Toxicological  ||| S:0 E:14 ||| JJ
assessment  ||| S:14 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
nanostructured  ||| S:28 E:43 ||| JJ
silica ||| S:43 E:49 ||| NN
.  ||| S:49 E:51 ||| .
II ||| S:51 E:53 ||| NNP
.  ||| S:53 E:55 ||| .
Enzymatic ||| S:55 E:64 ||| NNP
,  ||| S:64 E:66 ||| ,
biochemical  ||| S:66 E:78 ||| JJ
indices ||| S:78 E:85 ||| NNS
,  ||| S:85 E:87 ||| ,
state  ||| S:87 E:93 ||| NN
of  ||| S:93 E:96 ||| IN
antioxidative  ||| S:96 E:110 ||| FW
defence  ||| S:110 E:118 ||| FW
Nanostructured  ||| S:118 E:133 ||| FW
silica  ||| S:133 E:140 ||| FW
( ||| S:140 E:141 ||| -LRB-
SiO2 ||| S:141 E:145 ||| NNP
)  ||| S:145 E:147 ||| -RRB-
Aerosil  ||| S:147 E:155 ||| NNP
with  ||| S:155 E:160 ||| IN
the  ||| S:160 E:164 ||| DT
size  ||| S:164 E:169 ||| NN
of  ||| S:169 E:172 ||| IN
the  ||| S:172 E:176 ||| DT
primary  ||| S:176 E:184 ||| JJ
nanoparticles  ||| S:184 E:198 ||| NNS
( ||| S:198 E:199 ||| -LRB-
NPs ||| S:199 E:202 ||| NNP
)  ||| S:202 E:204 ||| -RRB-
of  ||| S:204 E:207 ||| IN
5-30  ||| S:207 E:212 ||| CD
nm ||| S:212 E:214 ||| NN
,  ||| S:214 E:216 ||| ,
in  ||| S:216 E:219 ||| IN
the  ||| S:219 E:223 ||| DT
form  ||| S:223 E:228 ||| NN
of  ||| S:228 E:231 ||| IN
ultrasound  ||| S:231 E:242 ||| NN
treated  ||| S:242 E:250 ||| VBN
water  ||| S:250 E:256 ||| NN
suspension  ||| S:256 E:267 ||| NN
was  ||| S:267 E:271 ||| VBD
administered  ||| S:271 E:284 ||| VBN
to  ||| S:284 E:287 ||| TO
rats  ||| S:287 E:292 ||| VB
of  ||| S:292 E:295 ||| IN
80  ||| S:295 E:298 ||| CD
±  ||| S:298 E:300 ||| CD
4  ||| S:300 E:302 ||| CD
g  ||| S:302 E:304 ||| CD
initial  ||| S:304 E:312 ||| JJ
body  ||| S:312 E:317 ||| NN
weight  ||| S:317 E:324 ||| NN
for  ||| S:324 E:328 ||| IN
the  ||| S:328 E:332 ||| DT
first  ||| S:332 E:338 ||| JJ
30  ||| S:338 E:341 ||| CD
days  ||| S:341 E:346 ||| NNS
by  ||| S:346 E:349 ||| IN
intragastric  ||| S:349 E:362 ||| JJ
gavage  ||| S:362 E:369 ||| NN
and  ||| S:369 E:373 ||| CC
then  ||| S:373 E:378 ||| RB
for  ||| S:378 E:382 ||| IN
62  ||| S:382 E:385 ||| CD
days  ||| S:385 E:390 ||| NNS
with  ||| S:390 E:395 ||| IN
diets  ||| S:395 E:401 ||| VBG
consumed  ||| S:401 E:410 ||| VBN
in  ||| S:410 E:413 ||| IN
doses  ||| S:413 E:419 ||| NNS
of  ||| S:419 E:422 ||| IN
0.1 ||| S:422 E:425 ||| CD
;  ||| S:425 E:427 ||| :
1.0 ||| S:427 E:430 ||| CD
;  ||| S:430 E:432 ||| :
10  ||| S:432 E:435 ||| CD
and  ||| S:435 E:439 ||| CC
100  ||| S:439 E:443 ||| CD
mg ||| S:443 E:445 ||| CD
/ ||| S:445 E:446 ||| CD
kg  ||| S:446 E:449 ||| JJ
body  ||| S:449 E:454 ||| NN
weight  ||| S:454 E:461 ||| NN
per  ||| S:461 E:465 ||| IN
day ||| S:465 E:468 ||| NN
.  ||| S:468 E:470 ||| .
The  ||| S:470 E:474 ||| DT
control  ||| S:474 E:482 ||| NN
group  ||| S:482 E:488 ||| NN
received  ||| S:488 E:497 ||| VBD
vehicle  ||| S:497 E:505 ||| NN
of  ||| S:505 E:508 ||| IN
nanomaterial  ||| S:508 E:521 ||| NNS
( ||| S:521 E:522 ||| -LRB-
NM ||| S:522 E:524 ||| NNP
) ||| S:524 E:525 ||| -RRB-
--deionized  ||| S:525 E:537 ||| JJ
water ||| S:537 E:542 ||| NN
.  ||| S:542 E:544 ||| .
There  ||| S:544 E:550 ||| EX
were  ||| S:550 E:555 ||| VBD
measured  ||| S:555 E:564 ||| VBN
in  ||| S:564 E:567 ||| IN
liver  ||| S:567 E:573 ||| NN
of  ||| S:573 E:576 ||| IN
ani-  ||| S:576 E:581 ||| JJ
mals  ||| S:581 E:586 ||| NNS
the  ||| S:586 E:590 ||| DT
content  ||| S:590 E:598 ||| NN
of  ||| S:598 E:601 ||| IN
total  ||| S:601 E:607 ||| JJ
cytochromes  ||| S:607 E:619 ||| JJ
P450  ||| S:619 E:624 ||| NN
and  ||| S:624 E:628 ||| CC
b5  ||| S:628 E:631 ||| CD
in  ||| S:631 E:634 ||| IN
the  ||| S:634 E:638 ||| DT
microsomal  ||| S:638 E:649 ||| JJ
fraction  ||| S:649 E:658 ||| NN
of  ||| S:658 E:661 ||| IN
liver ||| S:661 E:666 ||| NN
,  ||| S:666 E:668 ||| ,
activity  ||| S:668 E:677 ||| NN
( ||| S:677 E:678 ||| -LRB-
Vmax ||| S:678 E:682 ||| NNP
)  ||| S:682 E:684 ||| -RRB-
of  ||| S:684 E:687 ||| IN
microsomal  ||| S:687 E:698 ||| JJ
monooxygenases  ||| S:698 E:713 ||| NN
with  ||| S:713 E:718 ||| IN
the  ||| S:718 E:722 ||| DT
mixed  ||| S:722 E:728 ||| JJ
func-  ||| S:728 E:734 ||| JJ
tion  ||| S:734 E:739 ||| NN
of  ||| S:739 E:742 ||| IN
isoforms  ||| S:742 E:751 ||| CD
CYP1A1 ||| S:751 E:757 ||| CD
,  ||| S:757 E:759 ||| ,
1A2  ||| S:759 E:763 ||| NNP
and  ||| S:763 E:767 ||| CC
2B1  ||| S:767 E:771 ||| CD
on  ||| S:771 E:774 ||| IN
their  ||| S:774 E:780 ||| PRP$
specific  ||| S:780 E:789 ||| JJ
substrates ||| S:789 E:799 ||| NN
,  ||| S:799 E:801 ||| ,
the  ||| S:801 E:805 ||| DT
activity  ||| S:805 E:814 ||| NN
of  ||| S:814 E:817 ||| IN
conjugating  ||| S:817 E:829 ||| FW
liver  ||| S:829 E:835 ||| FW
enzymes  ||| S:835 E:843 ||| FW
glutathione-S-transferase  ||| S:843 E:869 ||| FW
and  ||| S:869 E:873 ||| CC
UDP-glucuronosyl-transferase  ||| S:873 E:902 ||| JJ
in  ||| S:902 E:905 ||| IN
microsomal  ||| S:905 E:916 ||| JJ
fraction  ||| S:916 E:925 ||| NN
and  ||| S:925 E:929 ||| CC
cytosol ||| S:929 E:936 ||| NN
,  ||| S:936 E:938 ||| ,
the  ||| S:938 E:942 ||| DT
total  ||| S:942 E:948 ||| NN
and  ||| S:948 E:952 ||| CC
non  ||| S:952 E:956 ||| JJ
sedimentable  ||| S:956 E:969 ||| JJ
activity  ||| S:969 E:978 ||| NN
of  ||| S:978 E:981 ||| IN
lysosomal  ||| S:981 E:991 ||| JJ
hydrolases  ||| S:991 E:1002 ||| NNS
( ||| S:1002 E:1003 ||| -LRB-
β-glucuronidase ||| S:1003 E:1018 ||| NNP
,  ||| S:1018 E:1020 ||| ,
β-galactozydase ||| S:1020 E:1035 ||| NNP
,  ||| S:1035 E:1037 ||| ,
arylsulphatase  ||| S:1037 E:1052 ||| VBG
A ||| S:1052 E:1053 ||| DT
,  ||| S:1053 E:1055 ||| ,
B ||| S:1055 E:1056 ||| NNP
) ||| S:1056 E:1057 ||| -RRB-
.  ||| S:1057 E:1059 ||| .
The  ||| S:1059 E:1063 ||| DT
content  ||| S:1063 E:1071 ||| NN
of  ||| S:1071 E:1074 ||| IN
PUFA ||| S:1074 E:1078 ||| NNP
's  ||| S:1078 E:1081 ||| POS
diene  ||| S:1081 E:1087 ||| JJ
conjugates  ||| S:1087 E:1098 ||| NN
and  ||| S:1098 E:1102 ||| CC
TBA-reactive  ||| S:1102 E:1115 ||| JJ
substances  ||| S:1115 E:1126 ||| NNS
in  ||| S:1126 E:1129 ||| IN
the  ||| S:1129 E:1133 ||| DT
blood  ||| S:1133 E:1139 ||| NN
plasma  ||| S:1139 E:1146 ||| NN
and  ||| S:1146 E:1150 ||| CC
the  ||| S:1150 E:1154 ||| DT
activity  ||| S:1154 E:1163 ||| NN
of  ||| S:1163 E:1166 ||| IN
antioxidative  ||| S:1166 E:1180 ||| JJ
enzymes  ||| S:1180 E:1188 ||| NNS
( ||| S:1188 E:1189 ||| -LRB-
glutathionperoxidase ||| S:1189 E:1209 ||| UH
,  ||| S:1209 E:1211 ||| ,
superoxidedismutase ||| S:1211 E:1230 ||| NN
,  ||| S:1230 E:1232 ||| ,
glutathionreductase ||| S:1232 E:1251 ||| NN
,  ||| S:1251 E:1253 ||| ,
katalase ||| S:1253 E:1261 ||| CD
)  ||| S:1261 E:1263 ||| -RRB-
in  ||| S:1263 E:1266 ||| IN
erytrocytes  ||| S:1266 E:1278 ||| NN
were  ||| S:1278 E:1283 ||| VBD
estimated ||| S:1283 E:1292 ||| VBN
.  ||| S:1292 E:1294 ||| .
A  ||| S:1294 E:1296 ||| DT
set  ||| S:1296 E:1300 ||| NN
of  ||| S:1300 E:1303 ||| IN
standard  ||| S:1303 E:1312 ||| JJ
biochemical  ||| S:1312 E:1324 ||| JJ
parameters  ||| S:1324 E:1335 ||| NNS
of  ||| S:1335 E:1338 ||| IN
blood  ||| S:1338 E:1344 ||| NN
serum  ||| S:1344 E:1350 ||| NNS
was  ||| S:1350 E:1354 ||| VBD
also  ||| S:1354 E:1359 ||| RB
examined  ||| S:1359 E:1368 ||| VBN
( ||| S:1368 E:1369 ||| -LRB-
total  ||| S:1369 E:1375 ||| JJ
protein ||| S:1375 E:1382 ||| NN
,  ||| S:1382 E:1384 ||| ,
albumin ||| S:1384 E:1391 ||| NN
,  ||| S:1391 E:1393 ||| ,
glucose ||| S:1393 E:1400 ||| NN
,  ||| S:1400 E:1402 ||| ,
creatinine ||| S:1402 E:1412 ||| NN
,  ||| S:1412 E:1414 ||| ,
urea ||| S:1414 E:1418 ||| NN
,  ||| S:1418 E:1420 ||| ,
uric  ||| S:1420 E:1425 ||| JJ
acid ||| S:1425 E:1429 ||| NN
,  ||| S:1429 E:1431 ||| ,
activities  ||| S:1431 E:1442 ||| NNS
of  ||| S:1442 E:1445 ||| IN
hepatic  ||| S:1445 E:1453 ||| JJ
transaminases ||| S:1453 E:1466 ||| NN
) ||| S:1466 E:1467 ||| -RRB-
.  ||| S:1467 E:1469 ||| .
The  ||| S:1469 E:1473 ||| DT
studies  ||| S:1473 E:1481 ||| NNS
revealed  ||| S:1481 E:1490 ||| VBD
changes  ||| S:1490 E:1498 ||| NNS
of  ||| S:1498 E:1501 ||| IN
a  ||| S:1501 E:1503 ||| DT
number  ||| S:1503 E:1510 ||| NN
of  ||| S:1510 E:1513 ||| IN
molecu  ||| S:1513 E:1520 ||| JJ
lar  ||| S:1520 E:1524 ||| JJ
markers  ||| S:1524 E:1532 ||| NN
that  ||| S:1532 E:1537 ||| WDT
could  ||| S:1537 E:1543 ||| MD
be  ||| S:1543 E:1546 ||| VB
interpreted  ||| S:1546 E:1558 ||| VBN
as  ||| S:1558 E:1561 ||| IN
unfavorable ||| S:1561 E:1572 ||| JJ
.  ||| S:1572 E:1574 ||| .
These  ||| S:1574 E:1580 ||| DT
include  ||| S:1580 E:1588 ||| VBP
isoforms  ||| S:1588 E:1597 ||| VBN
of  ||| S:1597 E:1600 ||| IN
CYP2B1  ||| S:1600 E:1607 ||| CD
activity  ||| S:1607 E:1616 ||| NN
decrease  ||| S:1616 E:1625 ||| NN
at  ||| S:1625 E:1628 ||| IN
a  ||| S:1628 E:1630 ||| DT
dose  ||| S:1630 E:1635 ||| FW
HM  ||| S:1635 E:1638 ||| FW
1-10  ||| S:1638 E:1643 ||| FW
mg ||| S:1643 E:1645 ||| FW
/ ||| S:1645 E:1646 ||| FW
kg  ||| S:1646 E:1649 ||| FW
of  ||| S:1649 E:1652 ||| IN
body  ||| S:1652 E:1657 ||| NN
weight ||| S:1657 E:1663 ||| NN
,  ||| S:1663 E:1665 ||| ,
decrease  ||| S:1665 E:1674 ||| NN
in  ||| S:1674 E:1677 ||| IN
the  ||| S:1677 E:1681 ||| DT
serum  ||| S:1681 E:1687 ||| JJ
content  ||| S:1687 E:1695 ||| NN
of  ||| S:1695 E:1698 ||| IN
total  ||| S:1698 E:1704 ||| JJ
protein ||| S:1704 E:1711 ||| NN
,  ||| S:1711 E:1713 ||| ,
albumin  ||| S:1713 E:1721 ||| NN
and  ||| S:1721 E:1725 ||| CC
glucose  ||| S:1725 E:1733 ||| JJ
levels  ||| S:1733 E:1740 ||| NNS
in  ||| S:1740 E:1743 ||| IN
a  ||| S:1743 E:1745 ||| DT
dose  ||| S:1745 E:1750 ||| NN
range  ||| S:1750 E:1756 ||| NN
of  ||| S:1756 E:1759 ||| IN
0.1-10  ||| S:1759 E:1766 ||| FW
mg ||| S:1766 E:1768 ||| FW
/ ||| S:1768 E:1769 ||| FW
kg ||| S:1769 E:1771 ||| FW
.  ||| S:1771 E:1773 ||| .
These  ||| S:1773 E:1779 ||| DT
changes  ||| S:1779 E:1787 ||| NNS
were  ||| S:1787 E:1792 ||| VBD
absent  ||| S:1792 E:1799 ||| VBN
at  ||| S:1799 E:1802 ||| IN
the  ||| S:1802 E:1806 ||| DT
maximum  ||| S:1806 E:1814 ||| JJ
dose  ||| S:1814 E:1819 ||| NN
of  ||| S:1819 E:1822 ||| IN
NM ||| S:1822 E:1824 ||| NNP
,  ||| S:1824 E:1826 ||| ,
which  ||| S:1826 E:1832 ||| WDT
did  ||| S:1832 E:1836 ||| VBD
not  ||| S:1836 E:1840 ||| RB
allow  ||| S:1840 E:1846 ||| VB
to  ||| S:1846 E:1849 ||| TO
clearly  ||| S:1849 E:1857 ||| RB
establish  ||| S:1857 E:1867 ||| VB
the  ||| S:1867 E:1871 ||| DT
dose-response ||| S:1871 E:1884 ||| JJ
.  ||| S:1884 E:1886 ||| .
The  ||| S:1886 E:1890 ||| DT
remaining  ||| S:1890 E:1900 ||| VBG
studied  ||| S:1900 E:1908 ||| VBN
fig  ||| S:1908 E:1912 ||| NNS
ures  ||| S:1912 E:1917 ||| VBP
resided  ||| S:1917 E:1925 ||| VBN
in  ||| S:1925 E:1928 ||| IN
the  ||| S:1928 E:1932 ||| DT
normal  ||| S:1932 E:1939 ||| JJ
range  ||| S:1939 E:1945 ||| NN
or  ||| S:1945 E:1948 ||| CC
experienced  ||| S:1948 E:1960 ||| JJ
changes  ||| S:1960 E:1968 ||| NNS
that  ||| S:1968 E:1973 ||| WDT
could  ||| S:1973 E:1979 ||| MD
not  ||| S:1979 E:1983 ||| RB
be  ||| S:1983 E:1986 ||| VB
interpreted  ||| S:1986 E:1998 ||| VBN
as  ||| S:1998 E:2001 ||| IN
toxic ||| S:2001 E:2006 ||| JJ
.  ||| S:2006 E:2008 ||| .
